Visual-Acuity
发表于 2025-3-28 16:25:09
Malignant Pleural Mesothelioma: History, Controversy, and Future of a Man-Made Epidemic,g non-invasive biomarkers such as mesothelin, the 13-protein signature in serum, fibulin-3, circulating microRNAs and the recently discovered BAP1 cancer syndrome are highlighted. The asbestos history is a lesson not be repeated, but here we also review recent in vivo and in vitro studies showing th
指耕作
发表于 2025-3-28 20:55:53
http://reply.papertrans.cn/17/1629/162898/162898_42.png
出没
发表于 2025-3-28 23:48:21
http://reply.papertrans.cn/17/1629/162898/162898_43.png
Notorious
发表于 2025-3-29 04:52:04
http://reply.papertrans.cn/17/1629/162898/162898_44.png
Prologue
发表于 2025-3-29 09:05:56
http://reply.papertrans.cn/17/1629/162898/162898_45.png
MEET
发表于 2025-3-29 14:37:56
3D Models of Mesothelioma in the Study of Mechanisms of Cell Survival,optotic family expression, and autophagy. In general, cells in a 3D setting show many differences compared to the same cells in a 2D monolayer. Many of these differences appear to contribute to cell survival. In many cases, these features can be shown to be more similar to those in the actual tumor.
柔声地说
发表于 2025-3-29 17:59:35
Biomarkers of Response to Asbestos Exposure,onchoalveolar lavage fluid. This makes direct exposure assessments very difficult. In contrast, biomarkers of response, which reflect a change in biologic function in response to asbestos exposure, have proved to be more useful. MM is the major biological response to asbestos that can be readily mon
deciduous
发表于 2025-3-29 23:33:51
Immunotherapeutic Approaches to Mesothelioma,Of these, the monoclonal antibody amatuximab and an antibody-drug conjugate anetumab ravtansine are undergoing registration trials. Ongoing research is focused on better understanding the antitumor responses to immune-based approaches and to prospectively identify patients who are more likely to res
WITH
发表于 2025-3-30 01:40:00
http://reply.papertrans.cn/17/1629/162898/162898_49.png
Sleep-Paralysis
发表于 2025-3-30 04:37:03
http://reply.papertrans.cn/17/1629/162898/162898_50.png